Double-dip CRISPR

In a new twist on CRISPR-based gene editing, a group at Harvard University has tweaked the system to simultaneously modify genes and regulate their expression using a single CRISPR-associated protein 9 (Cas9) enzyme.

Alejandro Chavez, a co-author on the study, told BioCentury the new method could be used in drug discovery to study the effects of multiple genes on disease phenotypes at one time, "allowing the analysis of these sorts of complex interactions at library scales." Chavez is a postdoc in the laboratory of George Church, a professor of genetics at Harvard...